ZhuZhou QianJin Pharmaceutical Co.,Ltd (SHA:600479)
China · Delayed Price · Currency is CNY 10.20
-0.07 (-0.68%)
May 20, 2026, 2:24 PM CST
SHA:600479 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 3,594 | 3,629 | 3,574 | 3,721 | 3,955 | 3,599 |
Other Revenue | - | - | 55.71 | 77.38 | 71.35 | 65.12 |
| 3,594 | 3,629 | 3,630 | 3,798 | 4,026 | 3,664 | |
Revenue Growth (YoY) | -1.10% | -0.03% | -4.44% | -5.66% | 9.89% | 1.02% |
Cost of Revenue | 1,824 | 1,859 | 1,951 | 2,051 | 2,296 | 2,038 |
Gross Profit | 1,770 | 1,770 | 1,679 | 1,748 | 1,731 | 1,626 |
Selling, General & Admin | 1,200 | 1,181 | 1,138 | 1,167 | 1,172 | 1,128 |
Research & Development | 163.11 | 185.6 | 220.2 | 149.07 | 113.82 | 108.72 |
Other Operating Expenses | 17.65 | 25.57 | 25.8 | 38 | 37.93 | 35.11 |
Operating Expenses | 1,380 | 1,392 | 1,390 | 1,372 | 1,326 | 1,271 |
Operating Income | 389.76 | 377.75 | 288.57 | 376.42 | 404.85 | 354.6 |
Interest Expense | - | - | -1.11 | -1.67 | -2.21 | -2.11 |
Interest & Investment Income | 49.01 | 44.19 | 51.11 | 70.19 | 30.7 | 33.64 |
Other Non Operating Income (Expenses) | 13.64 | 12.94 | -6.6 | -6.05 | -4.26 | -2.93 |
EBT Excluding Unusual Items | 452.41 | 434.89 | 331.97 | 438.9 | 429.08 | 383.19 |
Gain (Loss) on Sale of Investments | 1.63 | 2.41 | 0.63 | -1.6 | -1.3 | 4.72 |
Gain (Loss) on Sale of Assets | 2.04 | 1.88 | 0.05 | -0.94 | 0.17 | 33.11 |
Asset Writedown | -3.9 | -4.07 | -4.24 | - | - | - |
Other Unusual Items | - | - | 6.89 | 24.06 | 17.85 | 12.4 |
Pretax Income | 452.19 | 435.1 | 335.31 | 460.42 | 445.81 | 433.42 |
Income Tax Expense | 64.64 | 59.43 | 32.7 | 65.4 | 58.67 | 58.68 |
Earnings From Continuing Operations | 387.54 | 375.67 | 302.61 | 395.02 | 387.15 | 374.74 |
Minority Interest in Earnings | -79.4 | -89.38 | -71.85 | -74.61 | -84.64 | -72.68 |
Net Income | 308.14 | 286.29 | 230.76 | 320.41 | 302.51 | 302.06 |
Net Income to Common | 308.14 | 286.29 | 230.76 | 320.41 | 302.51 | 302.06 |
Net Income Growth | 29.63% | 24.07% | -27.98% | 5.92% | 0.15% | 1.68% |
Shares Outstanding (Basic) | 448 | 431 | 414 | 423 | 428 | 418 |
Shares Outstanding (Diluted) | 448 | 431 | 414 | 423 | 428 | 418 |
Shares Change (YoY) | 8.61% | 4.15% | -2.11% | -1.31% | 2.30% | -0.01% |
EPS (Basic) | 0.69 | 0.66 | 0.56 | 0.76 | 0.71 | 0.72 |
EPS (Diluted) | 0.69 | 0.66 | 0.56 | 0.76 | 0.71 | 0.72 |
EPS Growth | 19.35% | 19.13% | -26.43% | 7.32% | -2.11% | 1.69% |
Free Cash Flow | 359.98 | 356.08 | 351.45 | 399.13 | 699.04 | 413.69 |
Free Cash Flow Per Share | 0.80 | 0.83 | 0.85 | 0.94 | 1.63 | 0.99 |
Dividend Per Share | - | - | 0.360 | 0.350 | 0.350 | 0.600 |
Dividend Growth | - | - | 2.86% | - | -41.67% | -40.00% |
Gross Margin | 49.25% | 48.78% | 46.25% | 46.02% | 42.98% | 44.38% |
Operating Margin | 10.85% | 10.41% | 7.95% | 9.91% | 10.05% | 9.68% |
Profit Margin | 8.57% | 7.89% | 6.36% | 8.43% | 7.51% | 8.24% |
Free Cash Flow Margin | 10.02% | 9.81% | 9.68% | 10.51% | 17.36% | 11.29% |
EBITDA | 468.72 | 456.16 | 364.76 | 457.17 | 473.88 | 418.84 |
EBITDA Margin | 13.04% | 12.57% | 10.05% | 12.04% | 11.77% | 11.43% |
D&A For EBITDA | 78.95 | 78.4 | 76.19 | 80.74 | 69.03 | 64.24 |
EBIT | 389.76 | 377.75 | 288.57 | 376.42 | 404.85 | 354.6 |
EBIT Margin | 10.85% | 10.41% | 7.95% | 9.91% | 10.05% | 9.68% |
Effective Tax Rate | 14.30% | 13.66% | 9.75% | 14.21% | 13.16% | 13.54% |
Revenue as Reported | - | - | 3,630 | 3,798 | 4,026 | 3,664 |
Advertising Expenses | - | - | 12.82 | 10.56 | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.